ArticleACG case reports journal2026
Late-Onset Efavirenz-Induced Liver Toxicity in a 17-Year-Old, Filipino, Patient With HIV.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efavirenz is a non-nucleoside reverse transcriptase inhibitor widely used in HIV treatment. Although generally well-tolerated, rare cases of severe hepatotoxicity have been reported. We present a case of a patient on efavirenz-based highly active antiretroviral therapy who developed jaundice and marked transaminitis 1 year after initiation. Infectious, autoimmune, and toxic causes were ruled out, and genetic testing revealed no metabolic abnormalities. Treatment involved corticosteroids, immunosuppressants, and switching to dolutegravir, leading to resolution. This is the first documented case in the Philippines of delayed-onset efavirenz-induced liver injury, underscoring the importance of ongoing liver monitoring during antiretroviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.